Immunogenicity and safety of COVID-19 booster vaccination : A population-based clinical trial to identify the best vaccination strategy
Copyright © 2024. Published by Elsevier B.V..
BACKGROUND: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population-based evidence on the humoral immune response after booster vaccination is crucial to guide future vaccination strategies and in preparation for imminent COVID-19 waves.
METHODS: This multicenter, population-based cohort study included 4697 individuals ≥18 years of age who received a booster vaccination. Antibody levels against SARS-CoV-2 receptor binding domain (RBD) and neutralizing antibodies against wild-type (WT) virus and Omicron variants were assessed at baseline (day of booster vaccination) and after four weeks. Safety was evaluated daily within the first week using a participant-completed electronic diary. Antibody levels were compared across different vaccination strategies, taking into account individual host factors.
RESULTS: Our main model including 3838 participants revealed that individuals who received a booster with mRNA-1273 compared to BNT162b2 vaccine had a significantly higher increase (95 %CI) in anti-RBD-antibody levels (37,707 BAU/mL [34,575-40,839] vs. 27,176 BAU/mL [26,265-28,087]), and of neutralization levels against WT (1,681 [1490-1872] vs. 1141 [1004-1278] and Omicron variant (422 [369-474] vs. 329 [284-374]). Neutralizing antibody titres highly correlated with anti-RBD antibodies, with neutralizing capacity 4.4 fold higher against WT compared to Omicron. No differences in safety were found between the two booster vaccines.
CONCLUSION: Our study underlines the superiority of a booster vaccination with mRNA-1273, independent of the primary vaccination and therefore provides guidance on the vaccination strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
|---|---|
| Enthalten in: |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 173(2024) vom: 28. Feb., Seite 105661 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 19.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jcv.2024.105661 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369927222 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369927222 | ||
| 003 | DE-627 | ||
| 005 | 20240320235216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2024.105661 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369927222 | ||
| 035 | |a (NLM)38503118 | ||
| 035 | |a (PII)S1386-6532(24)00023-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sieghart, Daniela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and safety of COVID-19 booster vaccination |b A population-based clinical trial to identify the best vaccination strategy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population-based evidence on the humoral immune response after booster vaccination is crucial to guide future vaccination strategies and in preparation for imminent COVID-19 waves | ||
| 520 | |a METHODS: This multicenter, population-based cohort study included 4697 individuals ≥18 years of age who received a booster vaccination. Antibody levels against SARS-CoV-2 receptor binding domain (RBD) and neutralizing antibodies against wild-type (WT) virus and Omicron variants were assessed at baseline (day of booster vaccination) and after four weeks. Safety was evaluated daily within the first week using a participant-completed electronic diary. Antibody levels were compared across different vaccination strategies, taking into account individual host factors | ||
| 520 | |a RESULTS: Our main model including 3838 participants revealed that individuals who received a booster with mRNA-1273 compared to BNT162b2 vaccine had a significantly higher increase (95 %CI) in anti-RBD-antibody levels (37,707 BAU/mL [34,575-40,839] vs. 27,176 BAU/mL [26,265-28,087]), and of neutralization levels against WT (1,681 [1490-1872] vs. 1141 [1004-1278] and Omicron variant (422 [369-474] vs. 329 [284-374]). Neutralizing antibody titres highly correlated with anti-RBD antibodies, with neutralizing capacity 4.4 fold higher against WT compared to Omicron. No differences in safety were found between the two booster vaccines | ||
| 520 | |a CONCLUSION: Our study underlines the superiority of a booster vaccination with mRNA-1273, independent of the primary vaccination and therefore provides guidance on the vaccination strategy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Neutralizing antibodies | |
| 650 | 4 | |a Population-based study | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Hana, Claudia A |e verfasserin |4 aut | |
| 700 | 1 | |a Dürrschmid, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Heinz, Leonhard X |e verfasserin |4 aut | |
| 700 | 1 | |a Haslacher, Helmuth |e verfasserin |4 aut | |
| 700 | 1 | |a Zlesak, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Piccini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Manenti, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Montomoli, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Jorda, Anselm |e verfasserin |4 aut | |
| 700 | 1 | |a Fedrizzi, Clemens |e verfasserin |4 aut | |
| 700 | 1 | |a Hasenoehrl, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Zdravkovic, Andrej |e verfasserin |4 aut | |
| 700 | 1 | |a Anderle, Karolina |e verfasserin |4 aut | |
| 700 | 1 | |a Wiedermann, Ursula |e verfasserin |4 aut | |
| 700 | 1 | |a Drapalik, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Steinbrecher, Helmut |e verfasserin |4 aut | |
| 700 | 1 | |a Bergmann, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Firbas, Christa |e verfasserin |4 aut | |
| 700 | 1 | |a Jordakieva, Galateja |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Leonardi, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Pierleoni, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Ballini, Matilde |e verfasserin |4 aut | |
| 700 | 1 | |a Benincasa, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Marchi, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Trombetta, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Perkmann, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Crevenna, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Zeitlinger, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Bonelli, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Aletaha, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Radner, Helga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |d 1997 |g 173(2024) vom: 28. Feb., Seite 105661 |w (DE-627)NLM097223964 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:173 |g year:2024 |g day:28 |g month:02 |g pages:105661 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcv.2024.105661 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 173 |j 2024 |b 28 |c 02 |h 105661 | ||